{'fraction_non_alphanumeric': 0.03361344537815126, 'fraction_numerical': 0.013445378151260505, 'mean_word_length': 4.96, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hematology & Transfusion International Journal

Acquired hemophilia (AH) is a rare disease with an estimated prevalence of 1.48 cases/million people/year and a mortality rate of 9-22%, according to data obtained in the United Kingdom in a hemophilia surveillance study [1]. Unlike congenital hemophilia, in which the presentation is exclusive to men, AH has no gender bias. It is characterized by the occurrence of spontaneous bleeding in different sites of the body, with rare hemarthrosis and muscle bleeding. Family history has not yet been associated with the development of the disease [2].